Gene Therapy in Oncology – Thematic Research

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Gene Therapy Market

Gene therapy is the introduction of exogenous, genetic material into cells to treat a disease. Gene therapies provide therapeutic benefits to patients, especially those suffering from monogenic diseases. Cancers are generally not monogenic in origin, so gene therapies are more likely to be used to treat cancer by modifying gene regulation in tumorigenic pathways and expressing genes in cells that cause them to be recognized as foreign, or to elicit an immune response to tumorigenic cells.

Sales of products that comprise the categories of in vivo gene therapy are forecast to reach over $7B by 2027. The market for gene therapies, especially those using viral vectors, is expected to be slowed down by the high cost of therapies.

Gene Therapy Market Value by Class

Gene Therapy Market Value by Class

For more insights on the gene therapy market value, download a free report sample.

Gene Therapy in Oncology: Trends and Opportunities

The viral vector gene therapy field is expanding, but the high cost is an issue. However, the non-viral vector field is hindered by the inefficient delivery of transgenes. China’s Gendicine is the only in vivo viral gene therapy that is approved for cancer treatment. Insertional oncogenesis remains a constant concern after the death of a patient in 1999 from adenoviral-based Advexin. Current reimbursement programs struggle to cover the high cost of viral gene therapies, so new models are being considered.

There is a bigger window to manipulate non-viral vectors to improve stability and reduce transgene degradation before it reaches tumor cells. Non-viral vectors are viewed as safe because is lower immunogenicity compared to the use of viral vectors. When using viral technology, patients must be pre-screened for pre-existing immunity to certain viral strains. There is no need to do that when using non-viral vectors.

Gene Therapy in Oncology: Value Chain

The gene therapy in the oncology value chain consists of gene therapy vectors, therapeutic oligonucleotides, genome editing, and oncolytic viruses.

Therapeutic oligonucleotides: They are strands of DNA or RNA that either bind to receptors to stimulate an immune response or bind to RNA sequences to inhibit the translation of an oncogenic protein, or to indirectly promote the expression of a tumor suppressing protein.

Gene Therapy in Oncology Value Chain Analysis

Gene Therapy in Oncology Value Chain Analysis

For more insights on the gene therapy in oncology value chains, download a free report sample

Marketed Gene Therapy in Oncology Products in the 8MM by Types

Viral GT and oncolytic virus are the key types of marketed gene therapy in oncology products in the 8MM based on type. Oncolytic virus has the maximum number of marketed gene therapy in oncology products.

Marketed Gene Therapy in Oncology Products Analysis by Types

Marketed Gene Therapy in Oncology Products Analysis by Types

For more insights on the marketed gene therapy in oncology products by types, download a free report sample

Marketed Gene Therapy in Oncology Products in the 8MM by Therapy Areas

Head and neck cancers (HNCS), malignant pleural effusion, metastatic liver cancer, and metastatic melanoma are some of the leading therapy areas in the marketed gene therapy in oncology products in the 8MM. Head and neck cancer (HNCS) has the majority number of marketed products in terms of the number of approved agents.

Marketed Gene Therapy in Oncology Products Analysis by Therapy Areas

Marketed Gene Therapy in Oncology Products Analysis by Therapy Areas

For more insights on the marketed gene therapy in oncology products by therapy areas, download a free report sample

Gene Therapy in Oncology Pipeline Products in the 8MM by Types

Oncolytic virus, therapeutic oligonucleotide, viral vector, non-viral vector, and genome editing are the key types of gene therapy in oncology pipeline products. Oncolytic virus has the maximum number of pipeline products.

Gene Therapy in Oncology Pipeline Products Analysis by Types

Gene Therapy in Oncology Pipeline Products Analysis by Types

For more insights on the gene therapy in oncology pipeline products by types, download a free report sample

Gene Therapy in Oncology Pipeline Products in the 8MM by Therapy Areas

Various solid tumors, melanoma, pancreatic cancer, ovarian cancer, triple-negative breast cancer (TNBC), and hepatocellular carcinoma are some of the leading therapy areas in the gene therapy in oncology pipeline products. Various solid tumors have the majority number of pipeline products.

Gene therapy in Oncology Pipeline Products Analysis by Therapy Areas

Gene therapy in Oncology Pipeline Products Analysis by Therapy Areas

For more insights on the gene therapy in Oncology pipeline products by therapy areas, download a free report sample

Leading Gene Therapy Companies in Oncology

Some of the leading companies making their mark within the gene therapy in oncology theme are Amgen, SIBIono, Sunway Biotech, Candel, and CG Oncology.

Amgen: It is a biotechnology company that discovers, develops, manufactures, and markets innovative human therapeutics to treat patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas, including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience, and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television, and online media. Amgen is headquartered in Thousand Oaks, California, US.

Gene Therapy in Oncology Report Overview

Report Pages 104
Regions Covered Global
Key Trends Industry Trends and Regulatory Trends
Value Chains Gene Therapy Vectors, Therapeutic Oligonucleotides, Genome Editing, and Oncolytic Viruses
Key Types (Marketed Products) Viral GT and Oncolytic Virus
Key Therapy Areas (Marketed Products) Head And Neck Cancers (HNCS), Malignant Pleural Effusion, Metastatic Liver Cancer, and Metastatic Melanoma
Key Types (Pipeline Products) Oncolytic Virus, Therapeutic Oligonucleotide, Viral Vector, Non-Viral Vector, and Genome Editing
Key Therapy Areas (Pipeline Products) Various Solid Tumors, Melanoma, Pancreatic Cancer, Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), and Hepatocellular Carcinoma
Gene therapy Companies in Oncology Amgen, Sibiono, Sunway Biotech, Candel, and CG Oncology

Scope:

  • Overview of gene therapy including classification of therapy and technologies, regulatory and market access details, product & company profiles.
  • Quotes from US- and 5EU-based key opinion leaders and researchers.
  • Key topics covered for gene therapy in oncology in the 8MM include trends, value chain, market analysis, opportunities, challenges and unmet needs and high-value deals.
  • Pipeline analysis: Comprehensive data split across different phases and indications, emerging novel trends under development, and analysis of the most promising late-stage pipeline drugs for classes of gene therapy (Phase III and pre-registration).
  • Analysis of the key dynamics of the gene therapy market. Insightful review of the key industry drivers and challenges. Deals and R&D strategies covered in detail to highlight business opportunities.

Key questions answered:

  • What are the late-stage gene therapy pipeline agents in development for cancer? Which class of gene therapy drugs will have the highest peak sales, and why?
  • What are the current unmet needs that gene therapies can address in the treatment of cancer? What are the opportunities for R&D?
  • How is the field of gene therapy going to move forward? Which technologies are the most promising for combinations?
  • What is the regulatory landscape for gene therapies in the US, the 5EU, Japan and China?

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current deals and technologies to identify companies with the highest potential.
  • Develop business strategies by understanding the trends shaping and driving the global oncology gene therapy market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global oncology gene therapy market in the future.
  • Design your development strategy through a review of potential novel targets or combinations across indications.
  • Understand the challenges and strategies impacting the development of oncology gene therapy agents in preclinical studies and clinical trials.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the classes of gene therapy and indications that present maximum opportunities for consolidations, investments and strategic partnerships.

Amgen
SiBiono
Sunway Biotech
Candel
CG Oncology
Checkmate
Daiichi Sankyo
Ferring
FKD
Geron
Idera
Istari
VBL

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1. Table of Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

2.1. Key Findings

3. Gene Therapy Overview

3.1. What is Gene Therapy?

3.2. History of Gene Therapy Development in Cancer in the 8MM

3.3. Key Twitter Chat

4. Trends

4.1. Industry Trends – Gene Therapy Vectors

4.2. Industry Trends – Therapeutic Oligonucleotides

4.3. Industry Trends – Genome Editing

4.4. Industry Trends – Oncolytic Viruses

4.5. Regulatory Trends

5. Value Chain

5.1. Gene Therapy Value Chain

5.2. Gene Therapy Vectors

5.3. Therapeutic Oligonucleotides

5.4. Genome Editing

5.5. Oncolytic Viruses

5.6. Gene Therapy in Oncology Clinical Trials

6. Marketed Products

6.1. Marketed Gene Therapy Products for Cancer in the 8MM

6.2. Leading Gene Therapy Treatments in The 8MM

7. Pipeline Products

7.1. Gene Therapy Pipeline Products in the 8MM

7.2. Gene Therapy Pipeline Candidates

7.3. Late Stage Gene Therapy Candidates, 8MM

8. Market Analysis and Deals

8.1. Gene Therapy Market Analysis and Forecast by Class of Therapy

8.2. Top 10 Transaction Deals by Size during 2012-2021 in the Oncology Gene Therapy Space

8.3. Latest Transaction Deals in the Oncology Gene Therapy Space

8.4. Mergers and Acquisitions That Include Oncology Gene Therapy Assets: 2019 – 2021

8.5. Mergers and Acquisitions That Include Oncology Gene Therapy Assets: 2014 – 2018

9. Regulatory and Market Access

9.1. Gene Therapy in Clinical Trials

9.2. Regulatory – US

9.3. Market Access – US

9.4. Regulatory – Europe

9.5. Market Access – Europe

9.6. Regulation of Gene Therapy in the US and Europe

9.7. Regulatory and Market Access – Japan

9.8. Comparison of Early Access Schemes in the US, EU, and Japan

9.9. Regulatory and Market Access – China

10. Opportunities, Challenges, and Unmet Needs

10.1. Gene Therapy Vectors, Viral – Opportunities & Challenges

10.2. Gene Therapy Vectors, Non-viral – Opportunities & Challenges

10.3. Therapuetic Oligonucleotides – Opportunities & Challenges

10.4. Genome Editing – Opportunities & Challenges

10.5. Oncolytic Viruses – Opportunities & Challenges

10.6. Clinical Unmet Needs in Gene Therapy – Gap Analysis

10.7. Commercial Unmet Needs in Gene Therapy – Gap Analysis

10.8. Unmet Needs – KOLs Perspective

11. Companies

11.1. Drug Development Scorecard – Regenerative Medicine

11.2. Current Major Players

11.2.1. Amgen

11.2.2. SiBiono

11.2.3. Sunway Biotech

11.3. Future Players Based on Pipeline Strength

11.3.1. Candel

11.3.2. CG Oncology

11.3.3. Checkmate

11.3.4. Daiichi Sankyo

11.3.5. Ferring

11.3.6. FKD

11.3.7. Geron

11.3.8. Idera

11.3.9. Istari

11.3.10. VBL

12. Appendix

12.1. Bibliography

12.2. Primary Research

12.3. Key Themes Impacting the Pharmaceutical Industry

12.4. Our Thematic Research Methodology

12.5. About the Authors

12.6. Contact Us

12.7. Disclaimer

Frequently asked questions

Gene Therapy in Oncology – Thematic Research thematic reports
Currency USD
$995

Can be used by individual purchaser only

$1,995

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Gene Therapy in Oncology – Thematic Research was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Gene Therapy in Oncology – Thematic Research in real time.

  • Access a live Gene Therapy in Oncology – Thematic Research dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.